Viral recombinant vaccines to the E6 and E7 antigens of HPV-16

Abstract

Most cancerous lesions of the uterine cervix are linked to persistent infections with human papillomaviruses (HPV), most notably HPV-16 or -18. Vaccine-induced immune responses to the HPV early antigens E6 and E7, which contribute to cell transformation and are thus expressed in these cervical cancers, could potentially eradicate malignant cells. We generated recombinant vaccines based on E1-deleted adenovirus human strain 5 or on vaccinia virus strain Copenhagen expressing either the E6 or E7 oncoproteins of HPV-16. The different vaccines were compared in two experimental mouse tumor models employing Balb/c or C57BI/6 mice. Data presented here demonstrate that depending on the model either CD4+ or CD8+ T cells provide protection to tumor cell challenge, resulting in striking differences in the efficacy of the four vaccines under investigation. (C) 2000 Academic Press.